Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL127788 | 0.84 | TSHR (0.57) | TSHRALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL128626 | 0.82 | TSHR (0.59) | TSHRALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL129292 | 0.81 | TSHR (0.53) | TSHRALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL2408629 | 0.80 | TSHR (0.63) | TSHRALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL127994 | 0.80 | TSHR (0.57) | TSHRALDH1A1HPGDSMN1; SMN2TDP1 | |
| SCHEMBL27756219 | 0.79 | TSHR (0.52) | TSHRALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL10665241 | 0.79 | TSHR (0.52) | TSHRALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL128510 | 0.79 | TSHR (0.52) | TSHRMAPTHCAR2ATM | |
| SCHEMBL2409688 | 0.78 | TSHR (0.61) | TSHRALDH1A1HPGDSMN1; SMN2TDP1 | |
| SCHEMBL1882711 | 0.78 | TSHR (0.55) | TSHRALDH1A1HPGDSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023176458-A1 | DISINFECTING COMPOSITION CONTAINING THIAZOLE CARBOXYLIC ACID HYDRAZIDE COMPOUND | 石原産業株式会社 | 2023-09-21 | — | — | WO | disclosed |
| US-20140357654-A1 | METHODS OF TREATING SCHIZOPHRENIA WITH PHENYLALANINE ENAMIDE DERIVATIVE INHIBITORS OF a4 INTEGRIN POSSESSING A CYCLOBUTENE GROUP | AESTUS THERAPEUTICS, INC. (US) | 2014-12-04 | — | — | US | disclosed |
| EP-2775840-A1 | METHODS OF TREATING SCHIZOPHRENIA WITH PHENYLALANINE ENAMIDE DERIVATIVE INHIBITORS OF 4 INTEGRIN POSSESSING A CYCLOBUTENE GROUP | Aestus Therapeutics, Inc. (US) | 2014-09-17 | — | — | EP | disclosed |
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| WO-2013070842-A1 | METHODS OF TREATING SCHIZOPHRENIA WITH PHENYLALANINE ENAMIDE DERIVATIVE INHIBITORS OF α4 INTEGRIN POSSESSING A CYCLOBUTENE GROUP | AESTUS THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-7786177-B2 | Phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2010-08-31 | — | — | US | disclosed |
| US-7645770-B2 | Phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2010-01-12 | — | — | US | disclosed |
| US-20090186914-A1 | Phenylalanine Enamide Derivatives | UCB PHARMA, S.A. (BE) | 2009-07-23 | — | — | US | disclosed |
| US-7557130-B2 | Bicyclic heteroaromatic alanines | UCB PHARMA, S.A. (BE) | 2009-07-07 | — | — | US | disclosed |
| WO-1998031682-A1 | 4-(3-HETEROCYCLYL-1-BENZOYL)PYRAZOLES AND THEIR USE AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1998-07-23 | — | — | WO | disclosed |
| US-5670563-A | ORGANOTIN COMPOUND, PHOSPHORUS COMPOUND | CIBA-SPECIALTY CHEMICALS CORPORATION (US) | 1997-09-23 | — | — | US | disclosed |
| EP-0721454-A1 | NEW PYRAZOLE DERIVATIVES AS ANGIOTENSIN II ANTAGONIST | J. URIACH & CIA. S.A. (ES) | 1996-07-17 | — | — | EP | disclosed |
| WO-1996004273-A1 | NEW PYRAZOLE DERIVATIVES AS ANGIOTENSIN II ANTAGONIST | J. URIACH & CIA, S.A. (ES) | 1996-02-15 | — | — | WO | disclosed |
| EP-0361255-B1 | LIQUID-CRYSTAL MIXTURES CONTAINING AZULENE SQUARE ACID DYE | BASF Aktiengesellschaft (DE) | 1992-11-19 | — | — | EP | disclosed |
| US-5084592-A | Dyes for optical recording media | BASF AKTIENGESELLSCHAFT (DE) | 1992-01-28 | — | — | US | disclosed |
| US-5071588-A | Solubility; dichromism; ensures optimal absorption of wiring laser | BASF AKTIENGESELLSCHAFT (DE) | 1991-12-10 | — | — | US | disclosed |
| EP-0361255-A1 | Liquid-crystal mixtures containing azulene square acid dye | BASF Aktiengesellschaft (DE) | 1990-04-04 | — | — | EP | disclosed |
| EP-0310080-A2 | Azulene-squarillic dyes, azulenes as their intermediary products, and optical recording medium | BASF Aktiengesellschaft (DE) | 1989-04-05 | — | — | EP | disclosed |
| EP-0242767-A2 | N-dihydroindolyl ethyl-sulfon amides | BAYER AG (DE) | 1987-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357654-A1 | METHODS OF TREATING SCHIZOPHRENIA WITH PHENYLALANINE ENAMIDE DERIVATIVE INHIBITORS OF a4 INTEGRIN POSSESSING A CYCLOBUTENE GROUP | ITGA4, ITGB4, EPB41 | TSHR 1295/4885ALDH1A1 522/4885HPGD 2577/4885 |
| US-20090186914-A1 | Phenylalanine Enamide Derivatives | PAH, HRH3, PRLHR | TSHR 611/4885ALDH1A1 1822/4885HPGD 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.